论文部分内容阅读
将６８例经病理学证实的中晚期非小细胞肺癌（ＮＳＣＬＣ）患者随机分为Ａ、Ｂ两组，分别进行经留置导管支气管动脉内交替灌注化疗药物及细胞因子和单纯支气管动脉灌注（ＢＡＩ）治疗３～４次。结果表明，Ａ、Ｂ两组的近期有效率分别为９１１８％和４４１２％，二者具有显著性差异，无严重并发症。由此证明，留置导管及细胞因子与ＢＡＩ的有机配合，为中晚期ＮＳＣＬＣ的治疗提供了一种新的、有效方法
Sixty-eight patients with pathologically confirmed advanced non-small cell lung cancer (NSCLC) were randomly divided into two groups: group A and group B, which were treated with transcatheter arterial infusion of chemotherapy drugs, cytokines and bronchial artery infusion (BAI) Treatment of 3 to 4 times. The results showed that the short-term effective rates of group A and group B were 91.18% and 44.12% respectively, with significant difference between the two groups without serious complications. This proves that indwelling catheters and cytokines with organic coordination of BAI for the treatment of advanced NSCLC provides a new and effective method